Ligand Pharma (LGND) “Buy” Rating Maintained at Craig-Hallum; With $170.0 Target; Last Week Synchronoss Technologies, Inc. (SNCR) Coverage

November 15, 2017 - By Ellis Scott

Among 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ligand Pharmaceuticals has $160 highest and $103 lowest target. $143.40’s average target is -1.10% below currents $145 stock price. Ligand Pharmaceuticals had 21 analyst reports since September 3, 2015 according to SRatingsIntel. Deutsche Bank maintained it with “Hold” rating and $104 target in Tuesday, August 8 report. H.C. Wainwright reinitiated the stock with “Buy” rating in Tuesday, September 5 report. TH Capital maintained Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Friday, December 18 with “Buy” rating. On Thursday, November 19 the stock rating was maintained by Roth Capital with “Buy”. H.C. Wainwright maintained the shares of LGND in report on Wednesday, October 18 with “Buy” rating. The firm has “Buy” rating given on Monday, September 21 by Roth Capital. The firm has “Buy” rating given on Friday, March 11 by Roth Capital. The stock has “Buy” rating by Roth Capital on Friday, December 18. The company was maintained on Wednesday, September 30 by Roth Capital. The firm has “Buy” rating by H.C. Wainwright given on Thursday, October 5.

Among 8 analysts covering Synchronoss Technologies Inc. (NASDAQ:SNCR), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. Synchronoss Technologies Inc. had 16 analyst reports since July 31, 2015 according to SRatingsIntel. Stifel Nicolaus downgraded the stock to “Hold” rating in Thursday, February 4 report. Credit Suisse downgraded Synchronoss Technologies, Inc. (NASDAQ:SNCR) on Monday, May 22 to “Underperform” rating. The stock of Synchronoss Technologies, Inc. (NASDAQ:SNCR) has “Hold” rating given on Wednesday, October 18 by Stifel Nicolaus. The rating was initiated by Stephens with “Overweight” on Wednesday, August 10. The firm earned “Hold” rating on Wednesday, June 14 by Drexel Hamilton. Stifel Nicolaus maintained it with “Hold” rating and $10.0 target in Tuesday, September 19 report. JP Morgan initiated the shares of SNCR in report on Wednesday, January 25 with “Overweight” rating. Stifel Nicolaus maintained Synchronoss Technologies, Inc. (NASDAQ:SNCR) on Friday, June 23 with “Hold” rating. On Thursday, October 29 the stock rating was upgraded by Raymond James to “Strong Buy”. The stock of Synchronoss Technologies, Inc. (NASDAQ:SNCR) has “Buy” rating given on Wednesday, June 1 by Drexel Hamilton. See Synchronoss Technologies, Inc. (NASDAQ:SNCR) latest ratings:

18/10/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $12.0 Maintain
19/09/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $10.0 Maintain
20/09/2017 Broker: Deutsche Bank Rating: Hold New Target: $10.0
23/06/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $16.0000 Maintain
22/06/2017 Broker: J.P. Morgan Rating: Hold
14/06/2017 Broker: Drexel Hamilton Rating: Hold Downgrade
22/05/2017 Broker: Credit Suisse Old Rating: Neutral New Rating: Underperform Downgrade

Analysts await Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to report earnings on February, 22. They expect $1.09 EPS, up 826.67% or $1.24 from last year’s $-0.15 per share. LGND’s profit will be $23.00M for 33.26 P/E if the $1.09 EPS becomes a reality. After $0.55 actual EPS reported by Ligand Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 98.18% EPS growth.

Ligand Pharmaceuticals Incorporated is a biopharmaceutical firm that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The company has market cap of $3.06 billion. The Firm is involved in the development and licensing of biopharmaceutical assets. It has a 210.2 P/E ratio. The Firm employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

About 14 shares traded. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has declined 2.87% since November 15, 2016 and is downtrending. It has underperformed by 19.57% the S&P500.

Investors sentiment increased to 1.24 in 2017 Q2. Its up 0.06, from 1.18 in 2017Q1. It improved, as 22 investors sold Ligand Pharmaceuticals Inc. shares while 79 reduced holdings. 36 funds opened positions while 89 raised stakes. 22.57 million shares or 0.91% more from 22.37 million shares in 2017Q1 were reported. Piedmont Advisors Limited Co holds 4,116 shares. 182,440 are owned by Pax Ww Management Ltd Limited Liability Company. Da Davidson And holds 1,127 shares. Friedberg Mngmt invested in 4,220 shares. Intrust State Bank Na reported 2,157 shares. Northwestern Mutual Wealth Mgmt Com holds 0% or 28 shares. Wisconsin-based Campbell Newman Asset Mgmt has invested 0.05% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Pitcairn stated it has 0.03% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Pathstone Family Office Ltd Liability Com reported 0% stake. Moreover, Ajo L P has 0% invested in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 6,865 shares. Cim Mangement reported 5,203 shares or 0.22% of all its holdings. Howe And Rusling Inc reported 0.03% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). The New York-based State Teachers Retirement Sys has invested 0.01% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). 998,100 were reported by Knott David M. Bb&T Corporation owns 0.01% invested in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 2,696 shares.

Since June 9, 2017, it had 0 insider purchases, and 1 sale for $1.38 million activity. On Friday, June 9 the insider HIGGINS JOHN L sold $1.38 million.

Synchronoss Technologies, Inc. is a global software and services company, which provides technologies and services for the mobile transformation of business. The company has market cap of $443.32 million. The Company’s portfolio in the Consumer and Enterprise markets contains offerings, such as personal cloud, secure-mobility, identity management and scalable messaging platforms, products and solutions. It currently has negative earnings. The Company’s products and platforms are designed to enable multiple converged communication services to be managed across a range of distribution channels, including e-commerce, m-commerce, telesales, customer stores, indirect and other retail outlets.

It is down 60.71% since November 15, 2016 and is downtrending. It has underperformed by 77.41% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>